REGLITAZAR

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H20N2O5
Molecular Weight	392.4046
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(CCOC2=CC=C(CC3C(=O)NOC3=O)C=C2)N=C(O1)C4=CC=CC=C4

InChI

InChIKey=QBQLYIISSRXYKL-UHFFFAOYSA-N

InChI=1S/C22H20N2O5/c1-14-19(23-21(28-14)16-5-3-2-4-6-16)11-12-27-17-9-7-15(8-10-17)13-18-20(25)24-29-22(18)26/h2-10,18H,11-13H2,1H3,(H,24,25)

HIDE SMILES / InChI

Molecular Formula	C22H20N2O5
Molecular Weight	392.4046
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9599241 | https://www.ncbi.nlm.nih.gov/pubmed/9886766

Reglitazar is a dual agonist of PPAR alpha/PPAR gamma receptors. The drug was tested in phase II clinical trial, however, its development was terminated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor gamma 111 Target ID: P37231\|\|\|Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10821776	Agonist 2678		0.28 µM [EC50]
Peroxisome proliferator-activated receptor alpha 62 Target ID: Q07869 Gene ID: 5465.0 Gene Symbol: PPARA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10821776	Agonist 2678		5.4 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10821776	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Role of JTT-501, a new insulin sensitiser, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet.	1998 Apr	9562343
JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.	1998 Dec	9886766
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.	1999 Jan 8	9932726

Patents

Sample Use Guides

In Vivo Use Guide

Reglitazar (10-100 mg kg(-1) day(-1)) was administered orally to Zucker fatty rats for 7-21 days (preclinical study).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:41:58 UTC 2023` Edited by `admin` on `Fri Dec 15 15:41:58 UTC 2023`
Record UNII	P9UTN18JVV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

REGLITAZAR

Official Name

English

JTT-501

Code

English

JT-501

Code

English

reglitazar [INN]

Common Name

English

3,5-ISOXAZOLIDINEDIONE, 4-((4-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY)PHENYL)METHYL)-

Systematic Name

English

JTT-501.BETA.

Code

English

REGLITAZAR [JAN]

Common Name

English

Reglitazar [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98233